ClinicalTrials.gg
CompletedNCT01646827Updated Jul 31, 2014Results posted

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

A Phase 1 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-07-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
100th of 125
37 · median 130
Started
2012
with 3 others
Phase 1
13 of 126
none open now
Registered
73rd of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 100th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 13 in phase 1, and was the 73rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body

Read the detailed description

Extended-release gluteal intramuscular (IM) injection of aripiprazole has been tested in subjects with schizophrenia for safety and tolerability. This study will compare the gluteal IM aripiprazole injection with deltoid IM aripiprazole injection for safety and tolerability.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia, extended release antipsychotic
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia
  • Stabilized on oral antipsychotic medication
  • Good physical health
  • 18 to 35 kg/m2
  • Prior history of tolerating aripiprazole

Exclusion criteria

Exclusion Criteria:

  • Sexually active males who will not commit to utilizing 2 of the approved methods or who will not remain abstinent during the trial and for 180 days following the last dose of trial medication, or have not had an orchidectomy or sexually active females of who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 150 days following the last dose of trial medication. Abstinence will be permitted if it is confirmed and documented at every trial visit. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injections, implant, condom or sponge with spermicide.
  • Subjects who have met criteria for substance abuse or dependence within the past 180 days; including alcohol and benzodiazepines, but excluding caffeine and nicotine.
  • Subjects with a positive drug screen for cocaine or other drugs of abuse (excluding stimulants and other prescribed medications and marijuana).
  • Use of any psychotropic medications other than their current antipsychotic medication.
  • Use of any CYP2D6 and inhibitors, or CYP3A4 inducers within 14 days (fluoxetine 28 days) prior to dosing and for the duration of the trial.
  • Females who are pregnant or lactating.
  • Subjects who had participated in a previous IM depot trial within the last one year; or who had previously enrolled and received trial medication in an aripiprazole IM depot clinical trial.
  • Any major surgery within 30 days prior to enrollment.
  • Evidence of organ dysfunction or any deviation from normal in physical, electrocardiographic, or clinical laboratory examinations.
  • Subjects who have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on questions 4 or 5 (current or over the last 30 days) on the Baseline/Screening version of the Columbia Suicide Severity Rating Scale (C-SSRS).
  • Subjects currently in an acute relapse of schizophrenia.
  • Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder.
  • Subjects who were considered treatment-resistant to antipsychotic medication.
  • Subjects who have had electroconvulsive therapy within 2 months of administration of trial drug.
  • Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator.
  • Any other sound medical reason not to be entered into the trial, as determined by the clinical investigator.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Deltoid

    Deltoid injection site

    Drug: Aripiprazole IM Depot

  • Experimental
    Gluteal

    Gluteal injection site

    Drug: Aripiprazole IM Depot

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Aripriprazole

    Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.

    Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination

  2. Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Aripiprazole

    Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28, and AUC from time zero to infinity PK parameters.

    Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination

  3. Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole

    Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.

    Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination

  4. Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Dehydro-Aripiprazole

    Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28 and AUC from time zero to infinity PK parameters.

    Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination

Secondary outcomes

  1. Number of Participants Reporting Treatment Emergent Adverse Events (TEAE).

    Safety was measured according to standard adverse event collection as described in the adverse event section of the results.

    Time frame: Starting at the time the ICF was signed to Day 126/Early termination

  2. Number of Participants With Laboratory Values of Potential Clinical Relevance.

    The laboratory tests were collected and processed in accordance with directions from the clinical chemistry laboratory. Based on criteria for identifying laboratory values of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For fasting triglycerides: men: ≥ 160 mg/dL and women: ≥ 120 mg/dL; Fasting glucose: ≥ 115 mg/dL; Prolactin: \> upper limit of normal (ULN); Neutrophils: ≤ 1,500/mm3; and Creatine phosphokinase: ≥ 3 x ULN.

    Time frame: Day 1, Day 28, Day 126/Early termination

  3. Number of Participants With Vital Signs of Potential Clinical Relevance-Blood Pressure

    Vital sign assessment included orthostatic (supine and standing) blood pressure. Orthostatic assessments were made after participants had been in the supine position for at least 5 minutes and again after participants had been standing for 2 minutes, but not more than 3 minutes. Orthostatic hypotension defined as \>/= 20 mm Hg decrease in systolic blood pressure and \>/= 25 beats per minute increase in heart rate from supine to standing.

    Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination

  4. Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature

    Vital sign assessment included body temperature measured in centigrade(C). Temperatures \>=37.8°C and increase of \>= 1.1°C were recorded.

    Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination

  5. Number of Participants With Vital Signs of Potential Clinical Relevance-Heart Rate

    Vital sign assessment included heart rate (supine and standing). Heart rate with increase or decrease of \>/= 15 beats per minute were recorded.

    Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination

  6. Number of Participants With Electrocardiogram (ECG) Measurements of Potential Clinical Relevance

    Three 12 lead ECGs were performed approximately 5 minutes apart at each time point. The participant were supine and at rest (for at least 10 minutes) prior to the first ECG and will remain supine through the final ECG. Based on criteria for identifying ECG measurements of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For bradycardia: ≤ 50 beats per minute (bpm); and for increase in QTc: QTc ≥ 450msec.

    Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination

  7. Visual Analog Scale (VAS) Score at Day 1, Day 14, Day 28 and Last Visit.

    Injection site pain was assessed using a VAS, which was completed by the trial participant, and the investigator's assessment of most recent injection site, which was completed by the investigator. VAS is 100 mm line, 0=no pain, 100=unbearably painful.

    Time frame: Day 1, Day 14, Day 28 and last visit

  8. Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale.

    This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit.

    Time frame: Screening, Baseline, Week 1, Week 2, Week 8, Week 18 visit and Last visit.

07

Results

Posted Jul 31, 2014

Participant flow

This report presents results of a study on 37 adults with schizophrenia, conducted at 6 centers in the United States.

Participant flow — Overall Study
MilestoneAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Started1819
Completed1614
Not completed25
Withdrew: Lost to follow-up03
Withdrew: Physician decision12
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Aripriprazole

Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.

Time frame:
Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Aripriprazole
ng/mLAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Maximum Observed Plasma Concentration (Cmax) of Aripriprazole170 ± 58.6136 ± 70.3
PrimaryArea Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Aripiprazole

Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28, and AUC from time zero to infinity PK parameters.

Time frame:
Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Reported as:
Mean · ng day/mL
Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Aripiprazole
ng day/mLAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
AUC infinity (n=16,14)7590 ± 25907920 ± 2580
AUC 28 (n=16,17)3120 ± 11502380 ± 1410
AUC t (n=16,17)7360 ± 24207340 ± 2360
PrimaryMaximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole

Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.

Time frame:
Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole
ng/mLAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole51.7 ± 23.334.6 ± 13.2
PrimaryArea Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Dehydro-Aripiprazole

Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28 and AUC from time zero to infinity PK parameters.

Time frame:
Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Reported as:
Mean · ng day/mL
Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Dehydro-Aripiprazole
ng day/mLAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
AUC infinity (n=16,14)2520 ± 8362230 ± 630
AUC 28 (n=16,17)886 ± 445538 ± 305
AUC t (n=16,17)2420 ± 8051990 ± 603
SecondaryNumber of Participants Reporting Treatment Emergent Adverse Events (TEAE).

Safety was measured according to standard adverse event collection as described in the adverse event section of the results.

Time frame:
Starting at the time the ICF was signed to Day 126/Early termination
Reported as:
Number · Participants
Number of Participants Reporting Treatment Emergent Adverse Events (TEAE).
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Subjects with TEAEs1418
Subjects with serious TEAEs00
Subjects with severe TEAEs11
SecondaryNumber of Participants With Laboratory Values of Potential Clinical Relevance.

The laboratory tests were collected and processed in accordance with directions from the clinical chemistry laboratory. Based on criteria for identifying laboratory values of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For fasting triglycerides: men: ≥ 160 mg/dL and women: ≥ 120 mg/dL; Fasting glucose: ≥ 115 mg/dL; Prolactin: \> upper limit of normal (ULN); Neutrophils: ≤ 1,500/mm3; and Creatine phosphokinase: ≥ 3 x ULN.

Time frame:
Day 1, Day 28, Day 126/Early termination
Reported as:
Number · Participants
Number of Participants With Laboratory Values of Potential Clinical Relevance.
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
High fasting triglycerides (n=9,11)35
High fasting glucose (n=9,11)30
High prolactin (n=17,18)33
Low absolute neutrophils (n=17,18)12
High creatine phosphokinase (n=17,18)20
SecondaryNumber of Participants With Vital Signs of Potential Clinical Relevance-Blood Pressure

Vital sign assessment included orthostatic (supine and standing) blood pressure. Orthostatic assessments were made after participants had been in the supine position for at least 5 minutes and again after participants had been standing for 2 minutes, but not more than 3 minutes. Orthostatic hypotension defined as \>/= 20 mm Hg decrease in systolic blood pressure and \>/= 25 beats per minute increase in heart rate from supine to standing.

Time frame:
Day 1, Day 14, Day 28 and Day 126/Early termination
Reported as:
Number · Participants
Number of Participants With Vital Signs of Potential Clinical Relevance-Blood Pressure
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Increase >/=15 mmHg in diastolic standing BP01
Orthostatic hypotension00
SecondaryNumber of Participants With Vital Signs of Potential Clinical Relevance-Temperature

Vital sign assessment included body temperature measured in centigrade(C). Temperatures \>=37.8°C and increase of \>= 1.1°C were recorded.

Time frame:
Day 1, Day 14, Day 28 and Day 126/Early termination
Reported as:
Number · Participants
Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature00
SecondaryNumber of Participants With Vital Signs of Potential Clinical Relevance-Heart Rate

Vital sign assessment included heart rate (supine and standing). Heart rate with increase or decrease of \>/= 15 beats per minute were recorded.

Time frame:
Day 1, Day 14, Day 28 and Day 126/Early termination
Reported as:
Number · Participants
Number of Participants With Vital Signs of Potential Clinical Relevance-Heart Rate
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Heart rate: Supine: increase00
Heart rate: Supine: decrease00
Heart rate: Standing: increase00
Heart rate: Standing: decrease00
SecondaryNumber of Participants With Electrocardiogram (ECG) Measurements of Potential Clinical Relevance

Three 12 lead ECGs were performed approximately 5 minutes apart at each time point. The participant were supine and at rest (for at least 10 minutes) prior to the first ECG and will remain supine through the final ECG. Based on criteria for identifying ECG measurements of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For bradycardia: ≤ 50 beats per minute (bpm); and for increase in QTc: QTc ≥ 450msec.

Time frame:
Day 1, Day 14, Day 28 and Day 126/Early termination
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Measurements of Potential Clinical Relevance
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
premature ventricular contractions21
T-wave inversions22
Bradycardia and sinus bradycardia01
Abnormalities in QTc intervals00
SecondaryVisual Analog Scale (VAS) Score at Day 1, Day 14, Day 28 and Last Visit.

Injection site pain was assessed using a VAS, which was completed by the trial participant, and the investigator's assessment of most recent injection site, which was completed by the investigator. VAS is 100 mm line, 0=no pain, 100=unbearably painful.

Time frame:
Day 1, Day 14, Day 28 and last visit
Reported as:
Mean · Units on a scale
Visual Analog Scale (VAS) Score at Day 1, Day 14, Day 28 and Last Visit.
Units on a scaleAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Day 1: 0.5 hour pre-dose (n=17, 18)1.2 ± 3.40.8 ± 1.6
Day 1: 1 hour post-dose (n=17, 18)3.1 ± 7.31.7 ± 2.7
Day 14 (n=16, 18)1.3 ± 3.70.3 ± 0.8
Day 28 (n=16, 18)0.5 ± 1.10.5 ± 1.3
Last visit (n=17, 18)2.2 ± 7.20.5 ± 1.3
SecondaryNumber of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale.

This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit.

Time frame:
Screening, Baseline, Week 1, Week 2, Week 8, Week 18 visit and Last visit.
Reported as:
Number · Participants
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale.
ParticipantsAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Screening: Suicidality (n=17,18)47
Screening: Suicidal behaviour (n=17,18)25
Screening: Suicidal ideation (n=17,18)47
Baseline: Suicidality (n=17,18)00
Baseline: Suicidal behaviour (n=17,18)00
Baseline: Suicidal ideation (n=17,18)00
Week 1: Suicidality (n=17,18)00
Week 1: Suicidal behaviour (n=17,18)00
Week 1: Suicidal ideation (n=17,18)00
Week 2: Suicidality (n=16,18)00
Week 2: Suicidal behaviour (n=16,18)00
Week 2: Suicidal ideation (n=16,18)00
Week 8: Suicidality (n=16,18)00
Week 8: Suicidal behaviour (n=16,18)00
Week 8: Suicidal ideation (n=16,18)00
Week 18: Suicidality (n=16,14)00
Week 18: Suicidal behaviour (n=16,14)00
Week 18: Suicidal ideation (n=16,14)00
Last visit: Suicidality (n=17,18)00
Last visit: Suicidal behaviour (n=17,18)00
Last visit: Suicidal ideation (n=17,18)00

Adverse events

Collected over Events were recorded starting at the time the ICF is signed up to 125 days after the study drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot 400 mg: Deltoid—0/17 (0%)14/17 (82.4%)
Aripiprazole IM Depot 400 mg: Gluteal—0/18 (0%)18/18 (100%)
Most frequent other events
Showing 10 of 58
Most frequent other events
EventAripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: Gluteal
Injection site painGeneral disorders6/175/18
HeadacheNervous system disorders4/174/18
Musculoskeletal painMusculoskeletal and connective tissue disorders3/172/18
AkathisiaNervous system disorders3/173/18
SomnolenceNervous system disorders3/170/18
DizzinessNervous system disorders0/173/18
DiarrhoeaGastrointestinal disorders2/171/18
ToothacheGastrointestinal disorders2/171/18
Blood creatine phosphokinase increasedInvestigations2/170/18
ArthralgiaMusculoskeletal and connective tissue disorders2/171/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: GlutealTotal
Mean43.1 ± 11.045.9 ± 7.344.5 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot 400 mg: DeltoidAripiprazole IM Depot 400 mg: GlutealTotal
Female6410
Male121527
08

Study locations

6 sites
  • Comprehensive Clinical Development, Inc.
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • CNRI - San Diego
    San Diego, California 92102, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Comprehensive Clinical Development, Inc.
    Washington, District of Columbia 20016, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
09

References and documents

Publications

  • Raoufinia A, Peters-Strickland T, Nylander AG, Baker RA, Eramo A, Jin N, Bricmont P, Repella J, McQuade RD, Hertel P, Larsen F. Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. Int J Neuropsychopharmacol. 2017 Apr 1;20(4):295-304. doi: 10.1093/ijnp/pyw116. PubMed 28204607 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jul 20, 2012
Start
May 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Jul 31, 2014
Last update
Jul 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646827
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
May 2012
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Jul 31, 2014
Last update
Jul 31, 2014

Study contacts

Timothy Peters-Strickland, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion